The latest price target for IDEXX Laboratories (NASDAQ:IDXX) was reported by Piper Sandler on November 4, 2024. The analyst firm set a price target for $435.00 expecting IDXX to rise to within 12 months (a possible 3.93% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for IDEXX Laboratories (NASDAQ:IDXX) was provided by Piper Sandler, and IDEXX Laboratories reiterated their neutral rating.

The last upgrade for IDEXX Laboratories Inc happened on July 21, 2022 when Goldman Sachs raised their price target to $435. Goldman Sachs previously had a neutral for IDEXX Laboratories Inc.

The last downgrade for IDEXX Laboratories Inc happened on January 30, 2024 when Piper Sandler changed their price target from N/A to $525 for IDEXX Laboratories Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IDEXX Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IDEXX Laboratories was filed on November 4, 2024 so you should expect the next rating to be made available sometime around November 4, 2025.

While ratings are subjective and will change, the latest IDEXX Laboratories (IDXX) rating was a reiterated with a price target of $520.00 to $435.00. The current price IDEXX Laboratories (IDXX) is trading at is $418.55, which is out of the analyst’s predicted range.